Phase 1
One month after sharing promising interim-Phase I data at the American Society of Clinical Oncology, China-based Ascentage Pharma secured $150 million in Series C financing that will be used to support the development of its pipeline.
Shares of Advaxis are skyrocketing this morning after the company announced the U.S. Food and Drug Administration lifted the clinical hold on its Investigational New Drug Application for a Phase I/II cancer study.
A report recently published by the National Academies of Sciences, Engineering, and Medicine concluded that institutions and researchers should regularly and carefully evaluate whether and how to provide study results to participants.
Shares of Regulus Therapeutics saw something of a slight rally on Monday following a post-Independence Day corporate restructuring announcement that included the termination of 60 percent of its workforce, which caused a massive stock plummet.
Cytori Therapeutics, headquartered in San Diego, published data from its clinical trial of Adipose-Derived Regenerative Cells (ADRCs) in the journal Urology showing positive results.
An independent Data Safety Monitoring Board (DSMB) recommended that Titan Pharmaceuticals’ Phase I/II trial of its ropinirole implant for Parkinson’s disease continue with a second cohort of patients. However, the company has decided to temporarily halt the study and focus on another asset.
Ebola cases, as well as cases of other significantly lethal viral outbreaks that have occurred has spurred researchers to focus on the development of antivirals that can treat the illnesses.
Miracles, it seems, have a high price tag. At least, if those miracles are miracle drugs. There’s no doubt that trends in gene therapy and immuno-oncology are producing drugs that are as close to miraculous as we’re likely to get, doing a great job, generally, in beating back diseases that to this point were untreatable or didn’t respond well to other therapies.
The biopharma industry generally views vaccines to be low-margin investments. From a public health perspective, however, vaccines can be one of the best investment dollars.
This morning two companies announced deals that will yield potential benefits to multiple patient populations.
PRESS RELEASES